Per London expresses hope that EVOX's Huntington's therapy will be routinely used clinically within 10 years (by 2036).
“hopefully we can be at the point where this is a drug that is actually in the clinic and is used on routine basis, right? And, you know, we're certainly excited by that. Hopefully that can have a really transformative impact on the disease course in Huntington's.”
→ Read the source episode
Our resolution criterion
disputableEVOX's MSH3-targeting gene therapy receives regulatory approval and is prescribed for Huntington's disease patients by 2036
More from Beyond Biotech
Stuart Medina predicts Bio Spain 2026 Talent Day will exceed the 125 job interviews arranged in the previous year
Per London predicts EVOX will generate initial clinical data from Huntington's trials in 2028-2029.
Narissa Kreyer predicts Alterna will demonstrate AP-003 establishes functional protein and impacts biomarkers/efficacy endpoints in humans within five years
Per Lundin predicts EVOX's Huntington's gene editing therapy will be in routine clinical use within 10 years from 2026.
Laurent Levy predicts Nanobiotics will complete pancreatic, melanoma, and esophageal cancer trials before H1 2027
Narissa Kreyer predicts Alterna will conduct a clinical study in adult PKU patients demonstrating AP-003 protein generation and biomarker reduction
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.